The differences in tumor immune microenvironment between patients with MET-mutant and MET-non-mutant tumors. (IMAGE)
Caption
(A) Comparison of TMB, non-silent mutation rate, and silent mutation rate between MET-mutant and MET-non-mutant tumors. (B) mRNA expression levels of PD-1, PD-L1, and CTLA-4 in patients with MET-mutant and MET-non-mutant tumors. (C) The immune cell infiltration revealed by leukocyte fractions, lymphocyte fraction, and tumor-infiltrating lymphocyte fraction in MET-mutant and MET-non-mutant tumors. (D) The abundances of SNV neoantigens/Indel neoantigens and the diversity of TCR/BCR in MET-mutant and MET-non-mutant tumors. (E) Differences of 29 immune signatures estimated by ssGSEA between MET-mutant and MET-non-mutant tumors. (F) Comparison of 8 immune and 2 stromal cell populations between MET-mutant and MET-non-mutant tumors. (G) Expression differences of 16 MHC-related antigen-presenting molecules and 25 co-stimulators between MET-mutant and MET-non-mutant tumors. (H) Comparison of 48 chemokines and their receptors between MET-mutant and MET-non-mutant tumors. (I) Expression differences of 39 immune-stimulators between MET-mutant and MET-non-mutant tumors. BCR, B cell receptor; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; SNV, single nucleotide variants; TCR, T cell receptor; TIL, tumor-infiltrating lymphocyte; TMB, tumor mutation burden.
Credit
Genes & Diseases
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND